K W Pratz

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
    K W Pratz
    Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 24:1437-44. 2010

Detail Information

Publications1

  1. ncbi A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
    K W Pratz
    Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 24:1437-44. 2010
    ..Although sorafenib showed only modest clinical activity as a single agent in this heavily treated population, robust inhibition of FLT3 and ERK suggests that there may be a potential important role in combination therapies...